[Short-term and long-term remission after endoscopic transnasal adenomectomy in patients with acromegaly].

Q4 Medicine
A S Lutsenko, Zh E Belaya, E G Przhiyalkovskaya, A M Lapshina, A G Nikitin, V N Azizyan, O V Ivaschenko, A Yu Grigoriev, G A Melnichenko
{"title":"[Short-term and long-term remission after endoscopic transnasal adenomectomy in patients with acromegaly].","authors":"A S Lutsenko,&nbsp;Zh E Belaya,&nbsp;E G Przhiyalkovskaya,&nbsp;A M Lapshina,&nbsp;A G Nikitin,&nbsp;V N Azizyan,&nbsp;O V Ivaschenko,&nbsp;A Yu Grigoriev,&nbsp;G A Melnichenko","doi":"10.14341/probl13192","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Neurosurgery is the most effective treatment for acromegaly. As most of the patients present with macroadenomas, surgical treatment is not always successful, even with the expert level of a neurosurgeon. Assessment of the postoperative remission rates in acromegaly preoperative predictors of treatment efficacy is an urgent task of modern research.</p><p><strong>Aim: </strong>To assess the short-term and long-term remission of acromegaly after endoscopic transnasal adenomectomy in a tertiary medical center and assess preoperative predictors of the treatment effectiveness.</p><p><strong>Materials and methods: </strong>A single-center, prospective, uncontrolled study was conducted. We included patients with active acromegaly who did not receive medical therapy with somatostatin analogues and were referred for endoscopic transsphenoidal adenomectomy. Plasma miRNA expression was assessed by quantitative reverse transcription PCR. Postoperative samples of adenomas were sent for study, with the determination of the immunohistochemical staining for somatostatin receptors 2 and 5 subtypes and morphology was performed on postoperative adenoma samples.</p><p><strong>Results: </strong>The study included 44 patients: 32.8% men, median age 47.0 [34.0; 55.0], IGF-1 744.75 ng/ml [548.83;889.85], growth hormone 9.5 ng/ml [4.94; 17.07]. Tumor volume 832 mm3 [419.25; 2532.38]. Early postoperative remission was achieved in 35 patients (79.5%). Patients who achieved short-term remission had higher IGF-1 and basal growth hormone levels. Median follow-up was 19.0 months [12.5;29.0]. Long-term remission was achieved in 61.4% (27 patients), no remission in 9 (20.5%), recurrency in 2 patients (4.5%), 6 patients were to follow-up (13.6%). In patients with long-term remission, we observed lower growth hormone and IGF-1 levels. No differences in miRNA expression was observesd. The predictive value of basal GH before surgery for long-term remission was assessed: area under the curve 0.811 (95% CI: 0.649; 0.973). A cut-off value of 15.55 ng/mL corresponded to a sensitivity of 70.0% (34.8%; 93.3%), a specificity of 85.7% (67.3%; 96.0%), an accuracy of 81.6% (65 .7%; 92.3%), PPV 63.6% (39.3%; 82.5%), NPV 88.9% (75.4%; 95.4%).</p><p><strong>Conclusion: </strong>Rates of short-term and long-term remission after endoscopic transsphenoidal adenomectomy in our cohort is 79,5% и 61,4%, respectively, and is comparable with literature data for expert pituitary centers. Preoperative GH shows potential value in predicting the long-term remission of acromegaly, but further studies in a larger sample are needed to obtain more accurate cut-off values.</p>","PeriodicalId":20433,"journal":{"name":"Problemy endokrinologii","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939963/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Problemy endokrinologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/probl13192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Neurosurgery is the most effective treatment for acromegaly. As most of the patients present with macroadenomas, surgical treatment is not always successful, even with the expert level of a neurosurgeon. Assessment of the postoperative remission rates in acromegaly preoperative predictors of treatment efficacy is an urgent task of modern research.

Aim: To assess the short-term and long-term remission of acromegaly after endoscopic transnasal adenomectomy in a tertiary medical center and assess preoperative predictors of the treatment effectiveness.

Materials and methods: A single-center, prospective, uncontrolled study was conducted. We included patients with active acromegaly who did not receive medical therapy with somatostatin analogues and were referred for endoscopic transsphenoidal adenomectomy. Plasma miRNA expression was assessed by quantitative reverse transcription PCR. Postoperative samples of adenomas were sent for study, with the determination of the immunohistochemical staining for somatostatin receptors 2 and 5 subtypes and morphology was performed on postoperative adenoma samples.

Results: The study included 44 patients: 32.8% men, median age 47.0 [34.0; 55.0], IGF-1 744.75 ng/ml [548.83;889.85], growth hormone 9.5 ng/ml [4.94; 17.07]. Tumor volume 832 mm3 [419.25; 2532.38]. Early postoperative remission was achieved in 35 patients (79.5%). Patients who achieved short-term remission had higher IGF-1 and basal growth hormone levels. Median follow-up was 19.0 months [12.5;29.0]. Long-term remission was achieved in 61.4% (27 patients), no remission in 9 (20.5%), recurrency in 2 patients (4.5%), 6 patients were to follow-up (13.6%). In patients with long-term remission, we observed lower growth hormone and IGF-1 levels. No differences in miRNA expression was observesd. The predictive value of basal GH before surgery for long-term remission was assessed: area under the curve 0.811 (95% CI: 0.649; 0.973). A cut-off value of 15.55 ng/mL corresponded to a sensitivity of 70.0% (34.8%; 93.3%), a specificity of 85.7% (67.3%; 96.0%), an accuracy of 81.6% (65 .7%; 92.3%), PPV 63.6% (39.3%; 82.5%), NPV 88.9% (75.4%; 95.4%).

Conclusion: Rates of short-term and long-term remission after endoscopic transsphenoidal adenomectomy in our cohort is 79,5% и 61,4%, respectively, and is comparable with literature data for expert pituitary centers. Preoperative GH shows potential value in predicting the long-term remission of acromegaly, but further studies in a larger sample are needed to obtain more accurate cut-off values.

Abstract Image

Abstract Image

肢端肥大症患者经鼻内镜腺瘤切除术后的短期和长期缓解。
背景:神经外科手术是治疗肢端肥大症最有效的方法。由于大多数患者存在大腺瘤,手术治疗并不总是成功的,即使是专家级的神经外科医生。肢端肥大症术后缓解率的评估是术前治疗效果的预测指标,是现代研究的迫切任务。目的:评估三级医疗中心经鼻内镜腺瘤切除术后肢端肥大症的短期和长期缓解情况,并评估术前治疗效果的预测因素。材料和方法:采用单中心、前瞻性、非对照研究。我们纳入了未接受生长抑素类似物药物治疗的活动性肢端肥大症患者,并转行内镜下经蝶窦腺瘤切除术。采用定量反转录PCR检测血浆miRNA表达。送术后腺瘤标本进行研究,对术后腺瘤标本进行生长抑素受体2和5亚型的免疫组化染色及形态学检测。结果:纳入44例患者:男性32.8%,中位年龄47.0 [34.0;55.0], IGF-1 744.75 ng/ml[548.83;889.85],生长激素9.5 ng/ml [4.94;17.07]。肿瘤体积832 mm3 [419.25;2532.38]。术后早期缓解35例(79.5%)。获得短期缓解的患者有更高的IGF-1和基础生长激素水平。中位随访时间为19.0个月[12.5;29.0]。长期缓解者27例(61.4%),无缓解者9例(20.5%),复发者2例(4.5%),随访者6例(13.6%)。在长期缓解的患者中,我们观察到较低的生长激素和IGF-1水平。两组间miRNA表达无差异。评估术前基础GH对长期缓解的预测价值:曲线下面积0.811 (95% CI: 0.649;0.973)。临界值为15.55 ng/mL,灵敏度为70.0% (34.8%;93.3%),特异性为85.7% (67.3%;96.0%),准确率为81.6% (65.7%;92.3%), PPV 63.6% (39.3%;82.5%),净现值88.9% (75.4%;95.4%)。结论:在我们的队列中,内镜下经蝶窦腺瘤切除术后的短期和长期缓解率分别为79.5%和61.4%,与垂体专家中心的文献数据相当。术前GH在预测肢端肥大症的长期缓解方面具有潜在价值,但需要在更大的样本中进行进一步的研究以获得更准确的临界值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Problemy endokrinologii
Problemy endokrinologii Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
1.40
自引率
0.00%
发文量
59
期刊介绍: Since 1955 the “Problems of Endocrinology” (or “Problemy Endocrinologii”) Journal publishes timely articles, balancing both clinical and experimental research, case reports, reviews and lectures on pressing problems of endocrinology. The Journal is aimed to the most topical issues of endocrinology: to chemical structure, biosynthesis and metabolism of hormones, the mechanism of their action at cellular and molecular level; pathogenesis and to clinic of the endocrine diseases, new methods of their diagnostics and treatment. The Journal: features original national and foreign research articles, reflecting world endocrinology development; issues thematic editions on specific areas; publishes chronicle of major international congress sessions and workshops on endocrinology, as well as state-of-the-art guidelines; is intended for scientists, endocrinologists diabetologists and specialists of allied trade, general practitioners, family physicians and pediatrics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信